BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of November 11, 2026, BMY stock price climbed to $62.91 with 5,409,957 million shares trading.

BMY has a beta of 0.04, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.00 to the broad based SPY ETF.

BMY has a market cap of $128.59 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $13 billion in Revenue and $1.35 earnings per share. This beat revenue expectation by $374 million and exceeded earnings estimates by $.11.

In the last 3 years, BMY traded as high as $68.64 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, SCHD, VOO, IVV, SPY.

BMY has outperformed the market in the last year with a price return of +38.4% while the SPY ETF gained +12.6%. However, in the short term, BMY had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.0% vs -1.5% return in SPY. But in the last 2 weeks, BMY shares have fared better than the market returning +2.2% compared to SPY -1.3%.

BMY support price is $61.39 and resistance is $64.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.